Opinion|Videos|January 24, 2025
Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data
Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly discuss role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5